This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Modugno, M. Articles by Moll, J. Search for Related Content PubMed PubMed Citation Articles by Modugno, M. Articles by Moll, J.

Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358

Nerviano Medical Sciences S.r.l.-Oncology, Milan, Italy

Requests for reprints: Jürgen Moll, Nerviano Medical Sciences S.r.l.-Oncology, Viale Pasteur 10, I-20014 Nerviano, Milan, Italy. Phone: 39-331-58-1396; Fax: 39-331-58-1374; E-mail: jurgen.moll{at}nervianoms.com.

Mutations in the kinase domain of Bcr-Abl are the most common cause of resistance to therapy with imatinib in patients with chronic myelogenous leukemia (CML). Second-generation Bcr-Abl inhibitors are able to overcome most imatinib-resistant mutants, with the exception of the frequent T315I substitution, which is emerging as a major cause of resistance to these drugs in CML patients. Structural studies could be used to support the drug design process for the development of inhibitors able to target the T315I substitution, but until now no crystal structure of the T315I Abl mutant has been solved. We show here the first crystal structure of the kinase domain of Abl T315I in complex with PHA-739358, an Aurora kinase inhibitor currently in clinical development for solid and hematologic malignancies. This compound inhibits in vitro the kinase activity of wild-type Abl and of several mutants, including T315I. The cocrystal structure of T315I Abl kinase domain provides the structural basis for this activity: the inhibitor associates with an active conformation of the kinase domain in the ATP-binding pocket and lacks the steric hindrance imposed by the substitution of threonine by isoleucine. [Cancer Res 2007;67(17):7987–90]

This article has been cited by other articles:

				N. Steeghs, F. A.L.M. Eskens, H. Gelderblom, J. Verweij, J. W.R. Nortier, J. Ouwerkerk, C. van Noort, M. Mariani, R. Spinelli, P. Carpinelli, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors J. Clin. Oncol., October 20, 2009; 27(30): 5094 - 5101. [Abstract] [Full Text] [PDF]

				D. S. Boss, J. H. Beijnen, and J. H.M. Schellens Clinical Experience with Aurora Kinase Inhibitors: A Review Oncologist, August 1, 2009; 14(8): 780 - 793. [Abstract] [Full Text] [PDF]

				M. A. Seeliger, P. Ranjitkar, C. Kasap, Y. Shan, D. E. Shaw, N. P. Shah, J. Kuriyan, and D. J. Maly Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations Cancer Res., March 15, 2009; 69(6): 2384 - 2392. [Abstract] [Full Text] [PDF]

				R. E. Iacob, T. Pene-Dumitrescu, J. Zhang, N. S. Gray, T. E. Smithgall, and J. R. Engen Conformational disturbance in Abl kinase upon mutation and deregulation PNAS, February 3, 2009; 106(5): 1386 - 1391. [Abstract] [Full Text] [PDF]

				A. Quintas-Cardama and J. Cortes Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia Clin. Cancer Res., July 15, 2008; 14(14): 4392 - 4399. [Abstract] [Full Text] [PDF]

				A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I Blood, April 15, 2008; 111(8): 4355 - 4364. [Abstract] [Full Text] [PDF]

				P. Carpinelli, R. Ceruti, M. L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer Mol. Cancer Ther., December 1, 2007; 6(12): 3158 - 3168. [Abstract] [Full Text] [PDF]